ABVC BIOPHARMA, INC.
ABVCNasdaq
$1.25
↑ +3.3%Jul 17 close · end-of-day
Price
1Y↓ -64.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$31.8M
Enterprise Value
$31.7M
P/E
—
P/S
107.5
P/B
3.0
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$296,000.00
Net Income (TTM)
-$8.6M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-2713.1%
Net Margin
—
ROE
—
ROIC
-59.5%
Debt / Equity
0.0
Net Cash
$113,772.00
Return 1Y
-65.1%
Company profile
ABVC BioPharma, Inc. develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer. ABV-1504 has completed Phase II clinical trials for major depressive disorders. ABV1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.
- CEO
- Howard Doong
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- California
- Website
- abvcpharma.com
Earnings
ABVC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.060.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $483,045.00 | $355,797.00 | $969,783.00 | $152,430.00 | $509,589.00 | $296,000.00 |
| Gross profit | $464,329.00 | $350,711.00 | $683,368.00 | -$149,607.00 | $508,826.00 | — |
| Operating income | -$8.5M | -$11.7M | -$15.1M | -$6.8M | -$4.7M | -$7.2M |
| Net income | -$10.6M | -$12.8M | -$16.4M | -$7.8M | -$4.9M | -$7.9M |
| Diluted EPS | -$0.50 | -$0.51 | -$5.19 | -$1.80 | -$0.42 | -$0.39 |
| Operating cash flow | -$4.6M | -$7.6M | -$7.4M | -$4.2M | -$1.8M | -$3.0M |
| Free cash flow | — | -$7.6M | -$7.5M | -$4.2M | — | — |
| Gross margin | 96.1% | 98.6% | 70.5% | -98.1% | 99.9% | — |
| Operating margin | -1760.9% | -3290.1% | -1558.5% | -4439.2% | -923.3% | -2416.0% |
| Net margin | -2193.1% | -3608.5% | -1693.5% | -5109.3% | -962.1% | -2671.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $117,142.00 | $389,276.00 | $1,966.00 | — | — | $795,950.00 | — | — |
| Gross profit | $116,952.00 | $388,980.00 | $1,966.00 | — | — | $795,950.00 | — | — |
| Operating income | -$860,107.00 | -$302,316.00 | -$704,564.00 | -$693,005.00 | -$2.3M | -$2.0M | -$2.2M | -$1.6M |
| Net income | -$942,336.00 | -$394,769.00 | -$731,574.00 | -$842,075.00 | -$2.3M | -$2.0M | -$2.8M | -$1.6M |
| Diluted EPS | -$0.08 | -$0.03 | -$0.02 | -$0.06 | -$0.13 | -$0.09 | -$0.11 | -$0.06 |
| Operating cash flow | -$211,425.00 | $60,230.00 | -$702,134.00 | -$539,833.00 | -$894,174.00 | -$964,710.00 | -$587,582.00 | -$894,243.00 |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 99.8% | 99.9% | 100.0% | — | — | 100.0% | — | — |
| Operating margin | -734.2% | -77.7% | -35837.4% | — | — | -246.8% | — | — |
| Net margin | -804.4% | -101.4% | -37211.3% | — | — | -256.6% | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.